Showing 2971-2980 of 3288 results for "".
- Skin Cancer Foundation Hits the Roadhttps://practicaldermatology.com/news/skin-cancer-foundation-hits-the-road/2457771/The Skin Cancer Foundation kicks off the second year of its mobile education and screeing program called Destination: Healthy Skin. Starting Tuesday, May 15, in New York City, the tour will stop in 15 cities ov
- DermTech Partners with Melanoma Research Foundation to Support Miles for Melanomahttps://practicaldermatology.com/news/dermtech-partners-with-melanoma-research-foundation-to-support-miles-for-melanoma/2457781/DermTech, Inc. is partnering with the Melanoma Research Foundation in support of five Miles for Melanoma Runs/Walks held throughout the US, kicking off this month during Melanoma Awareness
- Parents Just Don't Understand Risks of Sun Exposure in Springhttps://practicaldermatology.com/news/parents-just-dont-understand-risks-of-sun-exposure-in-spring/2457791/Slightly more than 90 percent of parents underestimate the sun’s strength in spring and as a result, don’t adequately protect their children, according to a survey by parent magazine Kinderzeit.org. Specifically, 90.6 percent of parents polled tend to forget to apply sun
- First Androgenetic Alopecia Patient Dosed in a Pilot Study with Aclaris' ATI-502 Topicalhttps://practicaldermatology.com/news/first-androgenetic-alopecia-patient-dosed-in-a-pilot-study-with-aclaris-ati-502-topical/2457795/Aclaris Therapeutics, Inc. initiated a Phase 2 open-label study of ATI-502, a topical Janus Kinase (JAK) 1/3 inhibitor (ATI-502 Topical), in patients with androgenetic alopecia (AGA), a condition characterized by a genetically determined male/female-pattern baldness. This trial will
- Tattoo Removal Misperceptions Aboundhttps://practicaldermatology.com/news/tattoo-removal-misperceptions-abound/2457807/More than four in five adults with (86 percent) and without (82 percent) tattoos have misconceptions about tattoo removal, including confusion regarding side effects, cost and removability, according to a new Merz survey. In addition to not knowing how the process works, many underestimat
- Coming Soon to a City Near You: Sciton Inc.'s Bright Lights Big City BBL 2018 Tourhttps://practicaldermatology.com/news/coming-soon-to-a-city-near-you-sciton-incs-bright-lights-big-city-bbl-2018-tour/2457815/Sciton. Inc.’s Bright Lights Big City BroadBand Light (BBL) 2018 Tour is now in its third year. The 2018 Tour, featuring San Francisco dermatologist Patrick Bitter Jr., MD, kicks off in early June in For
- Skin of Color Society Reports Banner Yearhttps://practicaldermatology.com/news/skin-of-color-society-reports-banner-year/2457824/Kudos to the Skin of Color Society (SOCS) for a banner year. At its recent annual business meeting held in conjunction with the 2018 Annual Meeting of the American Academy of Dermatology, SOCS President Seemal R. Desai, MD, President &
- Proscia Inks Agreement to Bring Deep-Learning Technology to Dermatopathologyhttps://practicaldermatology.com/news/proscia-inks-agreement-to-bring-deep-learning-technology-to-dermatopathology/2457832/Proscia Inc., creators of AI-powered digital pathology software, signed a first-of-its-kind agreement with one of the largest dermatopathology labs in the country. This agreement provides Proscia with exclusive access to pathology slides and expert pathologist ground-truth data for an arr
- Hair Restoration Technique Updates Name to Reflect Surgical Nature of Procedurehttps://practicaldermatology.com/news/hair-restoration-technique-updates-name-to-reflect-surgical-nature-of-procedure/2457836/The International Society of Hair Restoration Surgery (ISHRS) has updated the terminology of the hair transplantation method known as FUE from Follicular Unit Extraction to Follicular Unit Excision. The ISHRS explains that this cha
- First Patient Dosed in Proof-of-Concept Trial of Topical by Design JAK Inhibitor SNA-125 for Atopic Dermatitishttps://practicaldermatology.com/news/first-patient-dosed-in-proof-of-concept-trial-of-topical-by-design-jak-inhibitor-sna-125-for-atopic-dermatitis/2457839/The first patient has been dosed in Sienna Biopharmaceuticals, Inc.'s Phase 1/2 proof-of-concept clinical trial of topical product candidate SNA-125 in the treatment of atopic dermatitis and the associated pruritus. SNA-125 is designed to inhibit Janus kinase 3, or JAK3, and tropomyosin recep